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Mutations in TNFRSF1A encoding TNF receptor 1 (TNFR1) cause the autosomal domi-
nant TNF receptor-associated periodic syndrome (TRAPS): a systemic autoinflammatory
disorder. Misfolding, intracellular aggregation, and ligand-independent signaling by
mutant TNFR1 are central to disease pathophysiology. Our aim was to understand the
extent of signaling pathway perturbation in TRAPS. A prototypic mutant TNFR1 (C33Y),
and wild-type TNFR1 (WT), were expressed at near physiological levels in an SK-Hep-1
cell model. TNFR1-associated signaling pathway intermediates were examined in this
model, and in PBMCs from C33Y TRAPS patients and healthy controls. In C33Y-TNFR1-
expressing SK-Hep-1 cells and TRAPS patients’ PBMCs, a subtle, constitutive upregu-
lation of a wide spectrum of signaling intermediates and their phosphorylated forms
was observed; these were associated with a proinflammatory/antiapoptotic phenotype.
In TRAPS patients’ PBMCs, this upregulation of proinflammatory signaling pathways was
observed irrespective of concurrent treatment with glucocorticoids, anakinra or etaner-
cept, and the absence of overt clinical symptoms at the time that the blood samples
were taken. This study reveals the pleiotropic effect of a TRAPS-associated mutant form
of TNFR1 on inflammatory signaling pathways (a proinflammatory signalome), which is
consistent with the variable and limited efficacy of cytokine-blocking therapies in TRAPS.
It highlights new potential target pathways for therapeutic intervention.
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Introduction
TNF receptor-associated periodic syndrome (TRAPS) is an
autoinflammatory disease that is associated with autosomal
dominant mutations in the gene encoding the TNF recep-
tor 1 (TNFR1) located on chromosome 12p13 [1]. More
than 91 different mutations in TNFR1 have been identified
(http://mf.igh.cnrs.fr/infevers/) and over 60% of these mutations
are associated with TRAPS [2].
The link between the presence of TNFR1 mutations and
the inflammatory conditions associated with TRAPS is still the
subject of intense investigations. Defective receptor shedding was
originally thought to reduce neutralization of TNF-α by soluble
TNFR1, thus resulting in the continuous inflammatory stimulus
that is notable in TRAPS [1]. However, defective shedding is vari-
able between different TNFR1mutants and different cell types and
thus cannot explain all the clinical features of TRAPS [3]. Mecha-
nisms associated with intracellular retention of the mutant TNFR1
and sequelae of this are now widely believed to be major factors
in the pathogenesis of TRAPS, including ligand-independent sig-
naling, misfolding and an unfolded protein response, induction of
reactive oxygen species (ROS) and impaired autophagy [4–13].
Recently, we demonstrated that there is upregulated expres-
sion of multiple proinflammatory genes in transfected cells
expressing mutant TNFR1 relative to those expressing normal
(WT) TNFR1 [8]. Our transcriptome studies demonstrated chronic
alteration in gene expression, but did not elucidate posttransla-
tional modifications such as phosphorylation or ubiquitination of
proteins, which are intimately associated with the acute control
of proinflammatory signaling. Therefore, studying the activity of
multiple signaling pathways that constitute a proinflammatory sig-
nalome is essential for a better understanding of the pathogenesis
of TRAPS.
TNFR1-TNF-α-mediated signaling is complex; a well estab-
lished consequence is the activation of the canonical pathway
of NF-κB leading ultimately to IκB degradation and the activa-
tion of the NF-κB p50/p65 heterodimer. Subsequent formation
of the proapoptosis, death-inducing signaling complex (complex
II or DISC) leads to caspase 8 activation [14, 15]. However,
normal physiological signal induction through TNFR1 has also
been demonstrated to activate the p38, Erk, and JNKmitogen acti-
vated protein kinases (MAPK) [16], the Jak/STAT and PI3K/Akt
pathways. This has been shown to occur through an increasing
number of intracellular associations, including sphingomyelinases
[17], SHP-1, c-Src, and Jak2 [18, 19]. The fate of the cell is,
therefore, determined by a complex balance between these acti-
vated pathways [20].
In TRAPS, both activation and inhibition of NF-κB have been
reported [7, 12, 21, 22] and differential activation of NF-κB sub-
unit members may be a feature of different TNFR1 mutations.
Furthermore, TRAPS-associated mutations lead to activation of
JNKs and P38 MAPK that may result from spontaneous signaling
by intracellular misfolded TNFR1 mutants or indirectly through
other mediators such as ROS that inactivate MAPK phosphatases
resulting in sustained MAPK signaling [11, 13, 23]. Resistance to
apoptosis is also detected in neutrophils and PBMCs isolated from
TRAPS patients [24, 25].
For many years, clinical management of TRAPS has involved
treatment with corticosteroids and, more recently, the use
of biological agents that block the action of proinflammatory
cytokines—particularly the TNF-binding agent etanercept and the
interleukin (IL)-1 receptor antagonist anakinra. A recent compre-
hensive review of the treatment of autoinflammatory diseases
demonstrates that, for TRAPS, corticosteroids, etanercept, and
anakinra show broadly similar levels of efficacy, with anakinra
being most successful at inducing a complete clinical response
(although response duration was not defined) [26]. However, for
many TRAPS patients, none of these therapies bring about per-
manent remission, or they induce only a partial response, and
5–15% of patients fail to respond to corticosteroids, etanercept or
anakinra [26]. We previously reported that levels of IL-6 are fre-
quently raised in TRAPS patients with a C33Y TNFR1 mutations
[27]; one of these patients, in whom either etanercept or anakinra
had limited efficacy, was treated with the IL-6 receptor blocking
antibody tocilizumab [28]. This patient initially responded well to
the treatment, although blood levels of proinflammatory cytokines
(TNF-α, IL-1α, IL-6, and IL-8) were not reduced [28]. Thus
cytokine blockade in TRAPS has variable, and often transient, effi-
cacy and does not target the central pathogenetic processes that
drive the inflammatory response.
We applied proteomic techniques to elucidate the variety
and complexity of intracellular signaling pathways affected by a
TRAPS-associated TNFR1 mutation. This study thus provides the
most comprehensive picture to date of the proinflammatory sig-
nalome that is constitutively activated by mutant forms of TNFR1,
even in TRAPS patients being treated with glucocorticoids and/or
cytokine-blocking biologics.
Results
Optimization of reverse phase protein microarrays
Reverse phase protein microarrays (RPPAs) use femtomolar quan-
tities of protein from clinical samples or cell lines; thus, optimiza-
tion is crucial to the reproducibility of the technique. To achieve
this goal SK-Hep-1 cells transfected with WT or mutant TNFR1
were treated with different stimulants (IL-1 (10 μg/mL), IL-6
(10 μg/mL), TNF-α (50 ng/mL) or LPS (20 μg/mL)) and were
pooled for use as a positive control lysate in the following set of
experiments.
Printing and blocking buffer optimization
To identify the optimal printing buffer, the positive control lysate
was serially diluted ten times in eight different buffers, namely,
PBS, PBS-0.01% Tween, PBS-5% glycerol, PBS + glycerol +
Tween, PBS + trehalose (50 mM) + glycerol + Tween, PBS +
trehalose, PBS + trehalose + Tween or SDS sample buffer.
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Figure 1. Validation of reverse phase protein microarray. (A) Positive control lysate was prepared from SK-Hep-1 cells transfected with WT or
mutant TNFR1 stimulated with IL-1 (10 μg/mL), IL-6 (10 μg/mL), and TNF-α (50 ng/mL) or LPS (20 μg/mL); cells were then lysed and the lysates
pooled. The lysates were serially diluted in eight different printing buffers, arrayed on 16- pad nitrocellulose-coated slides and probed for β-actin
by RPPA using infrared reporter-conjugate. (B) Multiple printing buffers were used to print the positive lysates on nitrocellulose slides and feature
signal intensities were assessed by probing the slide for β-actin using RPPA. Data are shown as mean of three replicates and the experiment was
repeated three timeswith similar results. All fluorescent signals are reported as arbitrary fluorescence units (AFU). (C) Fluorescent signal intensities
obtained for RPPA analysis using a range of blocking buffers. Data are shown as mean = SD of three samples in one experiment representative
of three independent experiments. (D) Intraslide reproducibility of RPPA: ten different lysates (S1-S10) were printed (replicate n = 6) on 16-pad
slides. A box and whisker plot is shown, with median represented by a black line within the box representing the interquartile range, using Tukeys
estimation for whisker length. The coefficient of variation (%) is indicated for each sample. (E) Feature-associated β-actin signal associated with
protein concentration of source lysate, up to 2 μg/mL. Positive control lysates were serially diluted and spotted on nitrocellulose slides. The slides
were probed by RPPA for β-actin, p-AKT Threonine, p-AKT serine, and p-PDK1. Data are shown as mean ± SD of 18 samples from one experiment
representative of three independent experiments. (F) Interslide reproducibility between signals from the same lysates (n = 30) printed on two
different nitrocellulose slides and probed for RPPA (R2 = 0.942). (G) Primary antibodies were validated using western blotting and strip images are
shown for selected antibodies in this study. Images are representative of two independent experiments.
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Samples were then printed onto 16-pad nitrocellulose slides. To
identify optimal blocking buffer, slides were blocked with four
commonly used buffers, namely, I-Block, 5% skimmed milk, 5%
BSA or non-animal protein (NAP) and then probed for β-actin.
Optimal features, with regular circular shapes and high signal
intensities, were achieved using SDS sample buffer (Fig. 1A and B).
The strongest signals, after background subtraction, were achieved
using I-Block (Fig. 1C). As a consequence, for all further exper-
iments, SDS sample buffer was used as the printing buffer and
I-Block as the blocking buffer.
Reproducibility and validity of RPPA
To test the reproducibility of microarray, both intraslide and inter-
slide variability was assessed. For intraslide validations, ten dif-
ferent positive control lysates were serially diluted in 1× SDS
sample buffer and printed onto 16-pad nitrocellulose slides in six
replicates each; slides were then processed for the detection of
β-actin. The coefficient of variation (CV%) within the replicates
was less than 12% for all the analyzed samples (Fig. 1D). Protein
concentration in the printing buffer and protein binding to the
array demonstrated a characteristic saturation curve, with protein
concentrations of over 1 μg/mL achieving>90%maximum signal
intensity (Fig. 1E).
Interslide reproducibility was examined by printing the lysates
used above onto two different 16-pad nitrocellulose slides in
six replicates. The printed slides were then probed for β-actin,
p-AKT-threonine, p-AKT-serine, and p-PDK1. The results indicated
high correlation coefficient between signals of corresponding
samples printed on the two different slides (r2 = 0.9401)
(Fig. 1F).
Validation of primary antibodies for microarray
experiments
A key challenge in RPPA is the availability of high specificity
antibodies that reveal only bands of the expected sizes. Positive
control lysate were run in SDS-PAGE, and transferred to nitrocel-
lulose membranes and assembled within a strip western device
(Miniblotter 20SL, Immunetics). Diluted antibodies (120 μL
per strip) were incubated with the individual wells (strips),
followed by secondary antiimmunoglobulin-reporter conjugate
and substrate. Only antibodies that stained for specific bands of the
correct molecular weights were included in this study (Fig. 1G).
The optimal dilution of each antibody was confirmed by microar-
ray using 64-pad nitrocellulose slides and infrared signal detection
(Table 1).
Constitutive activation of inflammatory signaling
pathways in SK-Hep-1 cells expressing mutant TNFR1
Intracellular signaling pathway intermediates that govern inflam-
mation (MAPK, PI3K/AKT, c-Src/Jak2/STAT3, NF-κB) and are
activated by TNFR1 were examined in cell lysates from
SK-Hep-1 cells transfected with C33Y TNFR1 or WT TNFR1 con-
structs. Separation of protein from the lysates was performed
by SDS-PAGE followed by electrotransfer to nitrocellulose mem-
branes (Invitrogen, UK). Immunoblotting was conducted using the
primary antibodies for the inflammatory target proteins such as
c-Src, STAT3, p-STAT3, p65, p50 p-AKT threonine, p-AKT serine,
CIAP, and p-P65. In addition, β-actin was used as an internal con-
trol for protein loading normalization for all samples. The western
blotting results revealed a generalized increase in expression of
the tested inflammatory markers in cells transfected with mutant
TNFR1 (C33Y) compared with cells transfected with WT TNFR1
(Fig. 2A and B). However, due to the limitations in scalability
and quantification of western blotting, the optimized RPPA was
applied to profile these signaling pathways within TNFR1 express-
ing cells. The same lysates used in western blotting above were
also tested by RPPA using the same primary antibodies. There was
a strong correlation between the results obtained from western
blotting and those from microarray, as significant elevations of
the tested inflammatory molecules were found in cells express-
ing mutant TNFR1 (C33Y) compared to WT TNFR1 (Fig. 2C–K).
These preliminary results allowed us to apply RPPA, with its high
throughput capability, to evaluate more signaling molecules in
response to different stimuli under a variety of conditions.
Stimulation with TNF-α does not significantly change
status of inflammatory signaling pathways
Both C33Y TNFR1- and WT TNFR1-transfected SK-Hep-1 cells
were treated with TNF-α under three different conditions: time
course of response to constant exposure to 10 ng/mL TNF-α;
pulse-chase response to 2 min exposure to 10 ng/mL TNF-α;
dose-response of exposure to various concentrations of TNF-α for
30 min. Cells were lysed and aliquots of the lysates were ana-
lyzed by western blotting (Fig. 3A); the remaining volumes of
the lysates were transferred to 384-well plates for array print-
ing. Arrays were probed with antibodies for the specific targets
in addition to probing for β-actin for standardization of the pro-
tein loading. RPPAs were analyzed with an infrared scanner and
normalized signal intensities were calculated using RPP analyzer
software. The results for each condition are shown in Figure 3B as
heat maps of the log2 relative expression levels detected for each
sample; they are also shown graphically for selected exemplar
molecules in Figure 3C–N as the mean ± SD of three different bio-
logical replicates; statistical data (two-way ANOVA) for Figure 3C–
N are shown in Supporting Information Table 2. Continuous stim-
ulation with 10 ng/mL TNF-α induced a slight, parallel increase
in levels of p-HSP27 in both C33Y and WT cells (Fig. 3C), but had
opposite effects on TRAF2 expression by the two cell lines, causing
decreased expression in C33Y cells and increased expression inWT
cells, thereby resulting in convergence of TRAF2 levels (Fig. 3D).
Pulse-chase with 10 ng/mL TNF-α had various effects on different
signaling molecules: it initially enhanced p-AKT-serine expression
in C33Y cells, whilst suppressing it in WT cells (Fig. 3E); it induced
suppression of p-C-Raf and p-GSK expression at later time points,
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Table 1. List of primary antibodies used in TNFR1 signaling study.
NF-κB Pathway PI3K/AKT Pathway MAPK Pathway Src/JAK/STAT3
Antibody Dilution Antibody Dilution Antibody Dilution Antibody Dilution
NF-κB p65 1:250 AKT 1:100 P38 MAP K 1:000 c-SRC 1:000
pNF-κB p65 1:100 P-AKT (T308) 1:50 pP38 MAP 1:000 pC-SRC 1:1000
p105/p50 NF-κB 1:1000 P-AKT (Ser.) 1:25 pHSP27 1:50 Jak2 1:000
IκB-α 1:250 p-eNos 1:500 ERK1/2 1:2000 pJak2 1:1000
P-IκB-α 1:500 pC-raf 1:1000 pERK1/2 1:2000 Stat3 1:1000
IKK-α 1:250 GSK-3β 1:500 pSAPK/JNK 1:1000 pStat3 1:500
IKK-β 1:250 pGSK-3β(Ser9) 1:500 pMEK3/MEK6 1:100
A20 1:500 PDK1 1:1000 pMAPKAPK 2 1:1000
c-IAP2 1:500 pPDK1 1:1000 pSek1/MKK4 1:250 c-FLIP 1:500
pTAKI 1:100 PTEN 1:1000 pC-Jun (Ser) 1:100 P-ATF2 1:250
pPTEN 1:1000 TRAF2 1:500 P-ELK-1 1:500
PI3K 110 1:250 Actin (Mouse) 1:1000
pPI3K P85 1:250 NU P98 1:1000
pBad 136 1:000 HSP 90 1:1000
All antibodies were rabbit antibodies and were purchased from Cell Signaling Technology. For western blotting, the antibodies were diluted 1:1000
in antibody diluent (Dako). For lysate microarray, they were diluted as shown in the table in the same dilution buffer.
with a greater effect on C33Y than WT cells (Fig. 3F and G); and it
induced a short-term rise in p-HSP27 levels in both C33Y and WT
cells (Fig. 3H). The dose-response experiments indicated that any
effects of TNF-α on signaling molecule expression were apparent
with 10 ng/mL TNF-α, and higher doses did not generally show
further effects (Fig. 3I–N).
Overall, the most significant factor causing elevation of the
inflammatory signaling intermediates (including PI3K, MAPK,
STAT3, Jak2/c-Src) and activation of transcription factors (such
as ATF, Jun, and ELK) was expression by the SK-Hep-1 cells of
the mutant C33Y TNFR1 compared with WT TNFR1 expression,
regardless of stimulation by TNF-α (Fig. 3). An exception to this
pattern was c-FLIP, which showed significantly higher levels in
WT than C33Y TNFR1-expressing cells (bottom row of the heat
maps in Figure 3B and N).
Increased NF-κB subunit activity in nuclear lysates of
SK-Hep-1 cells carrying mutant TNFR1
Lysates of nuclear subcellular fractions were prepared from the
SK-Hep-1 cells stably transfectedwith C33Ymutant TNFR1 or with
WT TNFR1, either without stimulation, or following stimulation
with 50 ng/mL TNF-α for various lengths of time. Western blot
analysis of these lysates to detect nuclear localization of NF-κB
subunits is shown in Figure 4A–E. Expression of NuP98 was used
as an internal control for normalization of nuclear protein loading.
Densitometric quantification of the western blots in Figure 4A
and B is shown in Figure 4C–E. These data show that nuclear
localization of NF-κB P50 and P65 is constitutively higher in C33Y
SK-Hep-1 transfectants than in WT. The nuclear levels of P50
increase in response to TNF-α in both C33Y andWT cells (Fig. 4C),
whereas nuclear P65 is increased in WT cells only to levels similar
to those seen in the nuclei of C33Y cells (Fig. 4D). Nuclear levels of
pP65 are much lower, but initially increase in both C33Y and WT
transfectants in response to TNF-α; they then fall again in C33Y
cells after 1 hour of stimulation, but continue to rise in WT cells
(Fig. 4E).
Nuclear fractions of C33Y- and WT TNFR1-transfected
SK-Hep-1 cells were also analyzed by RPPA for expression of the
NF-kB subunits P65, pP65, and P50; for members of the IKK reg-
ulatory system; and for the transcription factors p-ATF, p-ELK1,
and p-C-Jun (the findings are shown as a heat map in Figure 4F
and graphically in Figure 4G–P; statistical analysis by two-way
ANOVA shown in Supporting Information Table 3). All of these
proteins were constitutively upregulated in the nuclei of C33Y
cells compared with WT cells. Incubation with TNF-α slightly
increased nuclear expression of NF-κB P65 and P50 (Fig. 4G and I,
respectively; Supporting Information Table 3), and induced slight,
but statistically significant, changes in levels of IKB alpha and
pIKB alpha (Fig. 4L and M, respectively; Supporting Information
Table 3). By contrast, nuclear levels of NF-κB pP65 (Fig. 4H), IKK
alpha/beta (Fig. 4J and K), or the phosphorylated transcription
factors (Fig. 4N–P) were not affected by incubation with TNF-α
(Supporting Information Table 3). Thus, themost significant effect
on nuclear localization of transcription factors and regulatory
proteins was that of the C33Y TNFR1 mutation per se.
PBMC of C33Y-variant TRAPS patients confirm the
subtle activation of multiple inflammatory pathways
In order to corroborate the above findings, PBMCs from TRAPS
patients carrying C33Y mutation and PBMCs from sex- and age-
matched healthy controls were separated and lysed, and the
same inflammatory signaling intermediates were investigated. The
RPPA results reveal that the majority of the tested proteins and
their phosphorylated forms were constitutively upregulated in
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Figure 2. Comparison of western blot and RPPA detection of intracellular signaling intermediates and phosphorylation states in cultured
SK-Hep-1 cells. (A) SK-Hep-1 cells stably transfected with either normal TNFR1 (WT; right column) or TNFR1-C33Y variant (C33Y; left column) at
80% confluency were lysed and assessed for expression of signaling intermediates by SDS-PAGE and western blotting. Representative results from
three independent experiments are shown. Detection of β-actin was used as an internal control and as a normalizer for protein loading for all
samples used. (B) Densitometric quantification of samples shown in panel (A). Data are shown as mean + SD of three samples pooled from three
independent experiments. (C–K) Target protein abundance was assessed by RPPA using dual color fluorometric detection for the specific target
protein and β-actin, respectively. Scatter plots are shown, representing mean signal after background subtraction and normalization to β-actin
signal from each individual lysate spot of the technical replicates. The bar indicates the median signal, n = 8 biological replicates, or greater, for
each plot. The experiment was repeated three times with similar results. Significance values were derived using the Wilcoxon Test for repeated
measures. All fluorescent signals are reported as arbitrary fluorescence units (AFU), after normalization to β-actin signal.
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TRAPS patients compared with healthy controls with high levels
of statistical significance (p values range from 0.012 to 0.0002)—
these findings are shown as a heat map in Figure 5A, and graph-
ically in Figure 5B–Q. The only tested proteins not to differ sig-
nificantly between the TRAPS patients and controls were pC-Raf,
ERK1/2, pERK1/2, pMEK3/6, pHSP-27, and PTEN; indeed, even
for these proteins, two or more patients showed elevated levels,
which is consistent with the behavior of the SK-Hep-1 cells express-
ing C33Y-TNFR1 (Fig. 3). Thus, the results were mainly consistent
with the results obtained with transfected SK-Hep-1 cell lines, thus
supporting the use of the SK-Hep-1 cell line as amodel for studying
TRAPS.
It is important to note that the raised levels of signaling inter-
mediates in the TRAPS patients’ PBMCs occurred despite all seven
patients being free of overt clinical symptoms, and being on
treatment with potent antiinflammatory therapies at the time that
blood was taken (Fig. 5); four were being treated with anakinra
(IL-1 receptor antagonist—symbols shaded gray), twowith etaner-
cept (a TNF neutralizing agent — symbols shaded white) and one
with steroids (symbol shaded black). Thus, blocking the action of
proinflammatory cytokines associated with TRAPS (e.g. IL-1, TNF)
can improve clinical signs and symptoms, but not the underlying
activation of intracellular inflammatory signaling pathways.
Discussion
This study details, for the first time, the pleiotropic effect of a
TRAPS-associated mutant form of TNFR1 on multiple inflam-
matory signaling pathways — a proinflammatory signalome. It
is therefore the most comprehensive report to date evidencing
mutant forms of TNFR1 as promoters of a proinflammatory state
and may help to identify potential targets for future specific ther-
apeutic options for a variety of inflammatory disorders.
The examination of multiple TNFR1 signaling pathways by
reverse-phase protein microarray analysis methods demonstrates
not only that such large scale signaling studies can be performed
with relative ease, but that ourmodel system, SK-Hep-1 cells trans-
fected with C33Y or WT TNFR1 constructs, and C33Y TRAPS
patients’ PBMCs behave consistently with each other and show
pleiotropic alterations due to the presence of the C33Y mutated
form of TNFR1. Overall, there is a generalized increase in rel-
ative protein levels for a host of proinflammatory and anti-
apoptotic signaling intermediates (nonactivated and activated)
in both transfected cells and patients’ PBMCs carrying the C33Y
TNFR1 mutation. The C33Y-associated upregulation of signaling
intermediates is apparent with or without stimulation by TNF-α.
This is fully consistent with the ligand-independent signaling
hypothesis, with constitutive signaling by mutant TNFR1 driving
the cells into a sensitized, proinflammatory state.
The expression of C33Y-mutant TNFR1 influences
NF-κB related signaling, but also activation of PI3-kinase/AKT,
MEK/ERK, JNK, and P38 MAPK pathways and STAT3. Our
results are consistent with increased MAPK and JNK activation
reported previously [11]. However, our further observation of
increased levels of the inactive forms suggests that effects of
ROS in limiting phosphatase activity related to MAPKs is not the
sole reason for the increase in active forms seen, but that there
is a shift in the homeostatic balance within these pathways in
cells expressing the C33Y variant of TNFR1. It will be interesting
and important to extend these observations to cells expressing
other TRAPS-associated TNFR1 mutations, as we are currently
doing for the R92Q variant of TNFR1 (Abduljabbar et al., in
preparation).
Figure 6 summarizes the pathway associations of many of the
signaling intermediates and transcription factors investigated in
the present study in both the C33Y and WT TNFR1-transfected
SK-Hep-1 cell lines and in PBMCs from C33Y TNFR1 TRAPS
patients and healthy controls. Intracellular mutant TNFR1 is high-
lighted in red; signaling/transcription proteins that are signifi-
cantly upregulated in the TRAPS patients’ PBMCs are shown in
green and those that do not differ significantly between patients
and controls are shown in blue. The diagram also shows how the
relevant signaling pathways may be triggered physiologically by
exogenous TNF binding to WT TNFR1 at the cell surface, and/or
pathologically by constitutive activation of mutant, misfolded
TNFR1 in the cytoplasm. Furthermore, some of the pathways may
also be triggered via the interaction of other exogenous proinflam-
matory cytokines with their cell surface receptors — for example,
IL-6 (activating STAT3 and AKT1/2) and IL-1 (activating TRAF6)
(Fig. 6). Thus, the pathways shown could be activated directly by
ligand-independent activity of cytoplasmic mutant TNFR1 and/or
 Figure 3. Activation of inflammatory signaling intermediates by the TNFR1 C33Y mutation. (A) SK-Hep-1 transfectants were stimulated with
different concentrations of TNF-α (10, 20, 30, 40, and 50 ng/mL) for 30 min. Cell lysates from these cells were tested by western blotting for
detection of various signaling molecules. β-actin was used as an internal control for protein loading normalization and data shown are repre-
sentative of three independent experiments. (B) Blue (low) to yellow (high) heat maps representing the relative abundance of signaling pathways
intermediates using RPPA in SK-Hep-1 transfectants stimulated with TNF-α under three different conditions: Time, 10 ng/mL for 0, 10, 20, 30,
40, and 50 min; Pulse, 10 ng/mL for 2 min then lyse the cells after 0, 20, 40, 60, 80, and 100 min; Concentration, different concentrations of
TNF-α 0, 10, 20, 30, 40, and 50 ng/mL for 30 min, respectively. Each column of the heat map represents an SK-Hep-1 cell culture. Rows represent
the signaling molecules studied. Signal values represented on the color scale for the heat maps are log2 transformed from the AFU. Letters at
the side of the heat maps refer to the relevant graphs, depicting the mean ± SD signal intensities of that particular heat map row as follows:
(C) p-HSP27 (time), (D) TRAF2 (time), (E) pAKT serine (pulse), (F) p-C-Raf (pulse), (G) pGSK (pulse), (H) p-HSP27 (pulse), (I) PTEN (concentration),
(J) STAT3 (concentration), (K) phospho-STAT3 (concentration), (L) phospho-HSP27 (concentration), (M) Phospho-inositide 3 kinase P110 (concen-
tration) and (N) cFLIP (concentration). All fluorescent signals are reported as arbitrary fluorescence units (AFU), with β-actin signal normalisation.
Data in (C–N) are shown as mean ± SD of three samples pooled and are representative of three independent experiments. Statistical analysis of
RPPA data is presented in Supporting Information Table 2.
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indirectly by exogenous proinflammatory cytokines (TNF, IL-6,
IL-1). The latter could be generated as a consequence of the
constitutive proinflammatory effects of mutant TNFR1 itself
and/or due to exogenous stimuli such as infecting microbes. It
is relevant, in this context, that signaling pathways more distal
to those triggered directly by TNFR1 do not show significant
differences between the PBMCs of the TRAPS patients and
controls — i.e. c-Raf and Erk1/2 associated with IL-6 signaling,
and pMEKK3/6 in the IL-1 dependent TRAF6 pathway (Fig. 5
and 6). Furthermore, the negative regulator PTEN did not differ
significantly between patients and controls.
The model helps to explain why upregulation of multiple sig-
naling pathways was observed in TRAPS patients’ PBMCs in the
present study in spite of concurrent treatment with corticosteroids,
anakinra or etanercept and being free of overt clinical symptoms.
It may also help to explain why various cytokine/receptor neu-
tralizing biologics (e.g. etanercept, anakinra, tocilizumab) may
have variable effects in TRAPS patients or may be effective for
limited periods in particular patients [26, 29]. These biologics
inhibit the binding of the exogenous proinflammatory cytokines
to their cell surface receptors, thereby downregulating ligand-
dependent activation of particular signaling pathways. However,
in some patients, these may not be the key pathways driving the
inflammatory response and/or cells may adapt to the blockade
by diverting activity into other proinflammatory pathways. More
importantly, none of these neutralizing biologics will prevent
the constitutive activity of the cytoplasmic mutant TNFR1. This
explains why, in the present study, upregulation of signaling path-
ways was observed in TRAPS patients on biologic therapies and is
consistent with the observations that TRAPS patients may show a
clinical response to anticytokine or steroid treatments, but still
have symptoms of on-going subclinical systemic inflammation
[28]. Flares of clinical inflammation may then be due to syn-
ergy between the constitutive signaling activity of mutant TNFR1
and enhanced signaling by proinflammatory cytokines produced
in response to exogenous stimuli (e.g. infection) [11]. The impor-
tance of identifying new therapeutic modalities that directly target
the signaling pathways constitutively activated by mutant TNFR1
is thus apparent. It would also be desirable to extend the current
studies to TRAPS patients with different levels of disease activity,
and before and after treatment with particular therapeutic agents
to see how this affects the signaling pathways studied.
Activation of STAT3 is particularly interesting because this can
also be stimulated by IL-6 via Jak2 or c-Src. We have previously
shown that, amongst inflammatory cytokines, IL-6 in particular is
significantly elevated in C33Y TRAPS patients [27], and that the
anti-IL6 receptor therapeutic antibody tocilizumab can have ben-
efits in the clinical management of TRAPS [28]. Thus, enhanced
Jak/STAT signaling may be a consequence of the combined effects
of enhanced ligand-independent signaling by mutant TNFR1 and
an autocrine feedback loop resulting from IL-6 production. The
previously described ‘‘IL-6 amplifier’’ positive feedback loop of
inflammatory activity may be particularly relevant in this context
[30, 31]; this was first elucidated in the form of synergy between
IL-17A and IL-6, inducing increased IL-6 production by fibroblasts
through NF-κB and STAT3 signaling. However, other cytokines
and TLR-agonists may also synergize with IL-6 to enhance further
production of this important inflammatory cytokine — including
stimulation via TNFR1 [31]. We therefore hypothesize that, in
TRAPS, ligand-independent signaling by mutant TNFR1 stimu-
lates production of IL-6, and the two act synergistically to drive
the ‘‘IL-6 amplifier’’ cycle in tissue cells; this may help to explain
some of the tissue-localized inflammatory features of attacks in
TRAPS, including monocytic fasciitis and the associated migra-
tory erythematous skin rashes [32, 33]. Furthermore, since IL-1
can also drive IL-6 production by various cell types [34–36], this
hypothesis is also consistent with the therapeutic effect in TRAPS
of the IL-1 antagonist anakinra [28]. In addition, a recent case
report demonstrated the acute hyperresponsiveness of a TRAPS
patient’s PBMCs to inflammasome stimulation, resulting in signif-
icant IL1-β production [37], once again supporting both the case
for hyperresponsiveness to innate inflammatory signals other than
TNF-α and possible mechanisms by which IL-1 antagonists act in
TRAPS patients.
STAT3 activation also promotes its own gene expression, and
STAT3 has been shown to interact with NF-κB in both its phos-
phorylated (pSTAT3) and unphosphorylated (U-STAT3) forms.
U-STAT3 competes with IκB to bind nuclear NF-κB and can there-
fore act as an activator (as well as an inhibitor) of NF-κB driven
transcription, depending upon the promoter targeted and the
balance of pSTAT3/U-STAT3. Increased abundance of U-STAT3
is reported initially to sustain NF-κB stimulated IL-6/IL-8/CCL5
expression for a prolonged period [38, 39]; this is consistent with
the high levels of IL-8, as well as IL-6, that we have observed
 Figure 4. NF-κB activation in TNFR1-C33Y-expressing SK-Hep-1 cells. (A) TNFR1-C33Y-transfected or (B) TNFR1-WT-transfected, SK-Hep-1 trans-
fectants were stimulated with 50 ng/mL TNF-α for different times (0, 10 min, 20 min, 1, 2, 3, and 4 hours), lysed and assessed for NF-κB pathway
intermediates by chemiluminescent imaging using SDS-PAGE and western blot. Representative results of three experiments are shown. NuP98
was used as internal control normalizer of protein loading for nuclear lysate samples. Densitometric quantification of (C) nuclear P50, (D) nuclear
P65, and (E) nuclear phosphoP65 were obtained using the RPPA method. Data are shown as mean ± SD of three samples pooled from three
independent experiments. (F) Heat maps representing NF-κB signaling intermediates determined by RPPA in SK-Hep-1 transfectants stimulated
with 10 ng/mL TNF-α for various times (0, 10, 20, 30, 40, and 50 min). Each column represents separate SK-Hep-1 cell nuclear lysates organized by
the transfected variant, and then by time of stimulation; each row represents a separate signaling molecule. The blue to yellow heat map indicates
relative abundance from lower and higher levels, respectively. Signal values represented on the color scale for the heat maps are log2 transformed
from the AFU obtained. (G–P) Graphical representation of the signals visualized on the heat map (F): (G) P65, (H) p-P65, (I) P50, (J) IKKα, (K) IKKβ,
(L) IKBα, (M) p-IKBα, (N) p-ATF, (O) p-ELK1, and (P) p-C-Jun. All fluorescent signals are reported as arbitrary fluorescence units (AFU), with β-actin
signal normalization. Data are shown as mean ± SD of three samples pooled from three independent experiments. Statistical analysis of RPPA
data is presented in Supporting Information Table 3.
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in C33Y TRAPS patients [8, 27]. The increases in both U-STAT3
and pSTAT3, irrespective of the mechanism for their upregulation,
may therefore have significant consequences for the longevity of
the inflammatory response in TRAPS patients.
Our present findings indicate that a complex network of sig-
naling pathways are perturbed in both cultured cells and patients’
PBMCs that express a prototypic TRAPS-related TNFR1 mutation
(C33Y). Both the levels of the total protein and activated forms of
many TNFR1-related signaling molecules are elevated, suggesting
a shift in the homeostasis within cells to accommodate the ongoing
TNFR1-mediated signaling, resulting in cells which are potentially
more hyperacutely sensitive to other stimuli, yet not necessarily
to TNF-α itself. This complex signalome links NF-κB, p38, Jnk and
Erk, MAPK, Akt, Jak2, and STAT3 signaling pathways, and is con-
stitutively driven by the mutant TNFR1, irrespective of the proin-
flammatory cytokines secreted as a consequence of these intra-
cellular events. This helps to explain the diverse pathophysiology
of TRAPS, the variable and limited efficacy of cytokine-blocking
agents in the management of TRAPS, and offers new targets
and outcome measures for future therapeutic interventions. These
insights also have much wider implications for other inflammatory
and autoinflammatory diseases, where cytokine neutralizing ther-
apies are highly useful, but may have limited degree or duration
of efficacy. Delineation of signalomes in other autoinflammatory
diseases will also help to clarify whether the signalome defined in
this study is TRAPS-specific, or shares features with other autoin-
flammatory diseases.
Materials and methods
Cell culture, stimulation, and lysis
The human liver adenocarcinoma SK-Hep-1 endothelial-like cell
line (which naturally expresses low levels of TNFR1) was stably
transfected with WT or C33Y mutant TNFRSF1A gene constructs
as previously described [5]. Cells were grown in 6-well plates at
a density of 2 × 105 cells per well in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum, 100 units/mL of
penicillin, 10 mg/mL of streptomycin, and 5 μg/mL of blasticidin
(Invitrogen Life Technologies, USA) in a 37°C incubator with 5%
CO2 until 80% confluent. To produce lysates, cells were serum
starved for 24 hours before stimulation with TNF-α (R&D System)
as follows:
(i) TNF-α time course: TNF-α (10 ng/mL) was used to stimulate
the cells over a time course (0, 10, 20, 30, 40, and 50 min);
(ii) TNF-α pulse-chase experiment: cells were stimulated with
TNF-α (10 ng/mL) for 2 min and then immediately changed
to fresh medium and cells were lysed at different times (0, 20,
40, 60, 80, and 100 min); and
(iii) TNF-α concentration experiment: different concentrations of
TNF-α (0, 10, 20, 30, 40, and 50 ng/mL) were used for
30 min.
The cells were then washed with ice-cold phosphate buffered
saline (PBS), and lysed in 200 μL of RIPA buffer (Pierce, Thermo
Fisher Scientific) containing protease and phosphatase inhibitors
(Pierce, Thermo Fisher Scientific). Protein concentrations were
determined by BCA protein assay (Pierce, Thermo Fisher Sci-
entific). Lysates were mixed with 4× SDS (0.25 M Tris HCl
pH 6.8, 30% Glycerol, 8% SDS, and 10% 2-mercaptoethanol) at
a ratio of 3:1 and were boiled for 5 min at 95°C to obtain com-
plete protein denaturation prior to use in microarray or western
blotting.
Nuclear /cytoplasmic fractionation
NE-PER R© Nuclear and Cytoplasmic Extraction Reagents (Pierce,
Thermo Fisher Scientific) were used to separate the cytoplasm
from the nucleus to study the NF-κB signaling pathway. According
to the manufacturer’s recommendations, cells were washed twice
with ice-cold PBS and the cell pellet was resuspended in 200 μL of
cytoplasmic extraction reagent (cer1) mix containing protease and
phosphatase inhibitor cocktail, vortexed for 15 s and incubated on
ice for 10 min. Eleven microliters of ice-cold Cytosol Extraction
Buffer-B was added, vortexed for 5 s and incubated on ice for
1 min. After vortexing the samples were centrifuged for 5 min
at 16 000 × g. Supernatants (cytoplasmic extract) were trans-
ferred immediately to clean prechilled tubes and placed on ice.
Pellets (containing the nuclei) were washed twice with ice-cold
PBS to decrease contamination with cytoplasmic components, fol-
lowed by lysis with 100 μL of ice-cold Ner1 buffer mix containing
1× phosphatase and protease inhibitors and were vortexed for
15 s. Samples were then incubated on ice and the last step was
repeated every 10 min for 40 min. Samples were centrifuged at
16 000 × g for 10 min. Immediately, supernatants (nuclear
extract) were transferred to clean prechilled tubes. Protein con-
centrations were measured by BCA protein assay.
 Figure 5. Signaling pathway snapshot from TRAPS patient PBMCs. (A) PBMCs from TRAPS patients (P1–7) and controls (C1–9) were lysed and
assessed for intracellular signaling molecules using RPPA. Untreated PMBCs were lysed after separation from blood. Heat map showing various
inflammatory signaling pathway intermediates is shown. Rows represent the various signalingmolecules studied. Blue and yellow denotemarkers
that are present at lower and higher levels, respectively. (B–Q) Scatter plots representing measurement of selected target proteins from the heat
map data, including (B) p-AKT threonine, (C) pC-Raf, (D) PTEN, (E) STAT-3, (F) pSTAT3, (G) pP38, (H) ERK1/2, (I) pERK1/2, (J) pSAPK/JNK, (K) pMEK3/6,
(L)TRAF2, (M) TRAF6, (N) pTAK1, (O) PI3K110, (P) pPDK1, and (Q) pNFκB-p65. Data are shown as individual sample data (mean of four technical
replicates per sample) of nine patient samples or seven control samples. The black bar indicates the median signal for all samples in each group.
Signal represents arbitrary fluorescence units; AFU, after background subtraction and normalization to β-actin. Patient treatment is represented
by shading of the symbols: anakinra, gray; etanercept, white; steroid, black. Significance values were derived using the Wilcoxon Test for repeated
measures.
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Figure 6. Diagrammatic representation of key alterations in signaling molecule expression and phosphorylation states as determined by exami-
nation of both SK-Hep-1 cell line models and TRAPS patient PBMCs expressing the C33Y TNFR1 variant, compared with cells expressing the WT
TNFR1, or normal control sample PBMCs. The diagram does not show every target examined during this research project, but only indicates known
signaling pathway interactions between different molecules. Dashed lines represent interactions involving more than one intermediate. Thick
lines indicate where there is likely to be increased interaction and activation of downstream molecules or events. Signaling intermediates high-
lighted in green are those that are significantly upregulated in C33Y TRAPS patients’ PBMCs compared with those of healthy control individuals.
The signaling intermediates highlighted in blue show no significant difference in levels between patient and control PBMCs.
PBMC separation from TRAPS patient and control
blood samples
Blood samples were obtained following informed consent from
seven patients with the C33Y TNFR1 mutation and seven healthy
age and sex-matched controls. The experiments conformed to the
principles set out in the WMA Declaration of Helsinki and the NIH
Belmont report. All the patients were free from overt symptoms
of inflammation at the time that blood was taken. The mean age
of the patients was 41.7 years (range 32–58) with a male:female
ratio 5:2; four patients were being treated with anakinra, two
with etanercept, and one with steroids. The seven healthy age
and sex-matched controls were of mean age 44.7 years, range
29–65; male:female ratio 5:2. 20 mL blood was taken into a
Falcon polypropylene tube (Becton Dickinson, Lincoln Park, NJ,
USA) containing sterile citrate phosphate dextrose (ACD; Baxter
Health Care, Norfolk, UK). Bloodwas thenmixed 1:1 with PBS and
5 mL Histopaque was underlayered in 50 mL tubes followed by
centrifugation at 900 × g for 20 min. The PBMCs were removed,
washed twice in Hank’s buffered saline (total volume 25 mL) and
the cells were centrifuged at 400 × g for 10 min. The cell pellet
was finally washed with PBS, centrifuged and lysed with lysis
buffer (100 μL).
Immunoblotting
Proteins from the lysates were solubilized in 4× SDS loading buffer
and were heated for 5 min at 100°C. Equal amounts of protein
(50μg) were separated on Novex 12%Tris glycine polyacrylamide
gels (Invitrogen Life Technologies, USA) and transferred to nitro-
cellulose membranes. Membranes were blocked in PBS containing
0.1% Tween-20 and 5% nonfat dry milk powder, and incubated
with primary antibodies (diluted 1:1000 in 5% BSA/PBST). All
primary antibodies were purchased from Cell Signaling Technol-
ogy. Table 1 shows the list of the primary antibodies used in
western blot and microarray. Blots were incubated overnight at
4°C then washed with PBST, and incubated with swine anti-rabbit
immunoglobulin-HRP conjugate (DAKO) diluted 1:2000 in block-
ing buffer for 1 hour at room temperature. Following an additional
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PBST wash, membranes were incubated with Enhanced Chemilu-
minescence Detection reagent (ECL; Amersham, UK), exposed to
film (Kodak, Sigma Aldrich, UK), and developed. The densities of
resultant bands were measured with Un-SCAN-IT gel 5.3 software.
Reverse phase protein microarrays
Ten microlitres of cellular lysates were loaded into a 384-well
plate and serially diluted 5 times with 1× SDS buffer. Sam-
ples were spotted onto nitrocellulose-coated glass slides (Grace
Bio-labs) with a microarraying robot (MicroGrid 610, Digilab,
Marlborough, MA, USA). Incubation of the slides took place
overnight in blocking solution (0.2% I-block (Tropix, Bedford, MA,
USA), 0.1% Tween-20 in PBS) at 4°C with constant rocking. After
three washes of 5 min each, the slides were incubated with pri-
mary antibodies overnight at 4°Cwith shaking. In addition, β-actin
antibody (mouse antibody) was included as a control for protein
loading. After washing, slides were incubatedwith diluted infrared
Licor secondary antibodies (680 CW anti-mouse Ig antibody for
detection of β-actin and 800 CW anti-rabbit Ig antibody for detec-
tion of rabbit antibodies) for 30 min at room temperature in the
dark with shaking. Slides were washed then dried by centrifuga-
tion at 500× g for 5min and scannedwith a Licor Odyssey scanner
(LI-COR, Biosciences) at 21 μm resolution at 700 nm (red) and
800 nm (green). The resultant TIFF images were processed with
Genepix Pro-6 Microarray Image Analysis software (Molecular
Devices Inc.) to obtain fluorescence data for each feature and
generate standardized Genepix results (GPR) files. Protein signals
were finally determined with background subtraction and normal-
ization to the internal housekeeping targets using RPP analyzer, a
module within the R statistical language [40].
Statistical analysis
Two-way ANOVA using GraphPad Prism was applied to compare
the pattern of detection signaling molecules between C33Y and
WT cells across the dose response to TNF-α, pulse chase experi-
ments and time course experiments. Wilcoxon matched pairs test
using GraphPad Prism was applied to compare the level of expres-
sion of signaling molecules in unstimulated C33Y and WT cells, or
in TRAPS patients and healthy controls.
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